;PMID: 9820175
;source_file_1757.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..35] = [t:0..35]
;1)sentence:[e:41..132] = [t:41..132]
;2)section:[e:136..213] = [t:136..213]
;3)section:[e:217..319] = [t:217..319]
;4)sentence:[e:323..473] = [t:323..473]
;5)sentence:[e:474..556] = [t:474..556]
;6)sentence:[e:558..647] = [t:558..647]
;7)sentence:[e:648..838] = [t:648..838]
;8)sentence:[e:839..1036] = [t:839..1036]
;9)sentence:[e:1037..1094] = [t:1037..1094]
;10)sentence:[e:1095..1215] = [t:1095..1215]
;11)sentence:[e:1216..1380] = [t:1216..1380]
;12)sentence:[e:1381..1523] = [t:1381..1523]
;13)section:[e:1527..1571] = [t:1527..1571]

;section 0 Span:0..35
;Br J Cancer. 1998 Nov;78(9):1170-4.
(SEC
  (FRAG (NNP:[0..2] Br) (NNP:[3..4] J) (NNP:[5..11] Cancer) (.:[11..12] .)
        (CD:[13..17] 1998) (VBD:[18..24] Nov;78) (-LRB-:[24..25] -LRB-)
        (CD:[25..26] 9) (-RRB-:[26..27] -RRB-) (::[27..28] :) (CD:[28..32] 1170)
        (CD:[32..35] -4.)))

;sentence 1 Span:41..132
;Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral 
;platinum agent.
;[79..94]:cyp450:"cytochrome P450"
;[98..103]:substance:"JM216"
;[117..131]:substance:"platinum agent"
(SENT
  (NP-HLN
    (NP
      (ADJP
        (ADJP (JJ:[41..47] Potent))
        (CC:[48..51] and)
        (ADJP (AFX:[52..55] non) (HYPH:[55..56] -) (JJ:[56..64] specific)))
      (NN:[65..75] inhibition))
    (PP (IN:[76..78] of)
      (NP (NN:[79..89] cytochrome) (NN:[90..94] P450)))
    (PP (IN:[95..97] by)
      (NP
        (NP (NN:[98..103] JM216))
        (,:[103..104] ,)
        (NP (DT:[105..106] a) (JJ:[107..110] new) (JJ:[111..115] oral)
           (NN:[117..125] platinum) (NN:[126..131] agent))))
    (.:[131..132] .)))

;section 2 Span:136..213
;Ando Y, Shimizu T, Nakamura K, Mushiroda T, Nakagawa T, Kodama T, Kamataki
;T.
(SEC
  (FRAG (NNP:[136..140] Ando) (NNP:[141..142] Y) (,:[142..143] ,)
        (NNP:[144..151] Shimizu) (NNP:[152..153] T) (,:[153..154] ,)
        (NNP:[155..163] Nakamura) (NNP:[164..166] K,) (NNP:[167..176] Mushiroda)
        (NNP:[177..178] T) (,:[178..179] ,) (NNP:[180..188] Nakagawa)
        (NNP:[189..190] T) (,:[190..191] ,) (NNP:[192..198] Kodama)
        (NNP:[199..200] T) (,:[200..201] ,) (NNP:[202..210] Kamataki)
        (NNP:[211..213] T.)))

;section 3 Span:217..319
;Division of Drug Metabolism, Faculty of Pharmaceutical Sciences, Hokkaido 
;University, Sapporo, Japan.
(SEC
  (FRAG (NNP:[217..225] Division) (IN:[226..228] of) (NNP:[229..233] Drug)
        (NNP:[234..244] Metabolism) (,:[244..245] ,) (NNP:[246..253] Faculty)
        (IN:[254..256] of) (NNP:[257..271] Pharmaceutical)
        (NNPS:[272..280] Sciences) (,:[280..281] ,) (NNP:[282..290] Hokkaido)
        (NNP:[292..302] University) (,:[302..303] ,) (NNP:[304..311] Sapporo)
        (,:[311..312] ,) (NNP:[313..318] Japan) (.:[318..319] .)))

;sentence 4 Span:323..473
;Bis-acetato-ammine-dichloro-cyclohexylamine-platinum (IV), JM216, is the
;first  antineoplastic platinum compound that can be given to patients
;orally.
;[323..380]:substance:"Bis-acetato-ammine-dichloro-cyclohexylamine-platinum
;(IV)"
;[382..387]:substance:"JM216"
;[403..435]:substance:"antineoplastic platinum compound"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[323..375] Bis-acetato-ammine-dichloro-cyclohexylamine-platinum)
          (-LRB-:[376..377] -LRB-) (CD:[377..379] IV) (-RRB-:[379..380] -RRB-))
      (,:[380..381] ,)
      (NP (NN:[382..387] JM216)))
    (,:[387..388] ,)
    (VP (VBZ:[389..391] is)
      (NP-PRD
        (NP (DT:[392..395] the) (JJ:[396..401] first)
           (JJ:[403..417] antineoplastic) (NN:[418..426] platinum)
           (NN:[427..435] compound))
        (SBAR
          (WHNP-1 (WDT:[436..440] that))
          (S
            (NP-SBJ-1 (-NONE-:[440..440] *T*))
            (VP (MD:[441..444] can)
              (VP (VB:[445..447] be)
                (VP (VBN:[448..453] given)
                  (NP-1 (-NONE-:[453..453] *))
                  (PP-DTV (TO:[454..456] to)
                    (NP (NNS:[457..465] patients)))
                  (ADVP-MNR (RB:[466..472] orally)))))))))
    (.:[472..473] .)))

;sentence 5 Span:474..556
;Several  phase II clinical trials of JM216 monotherapy have already been
;reported.
;[511..516]:substance:"JM216"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[474..481] Several)
        (NML (NN:[483..488] phase) (CD:[489..491] II))
        (JJ:[492..500] clinical) (NNS:[501..507] trials))
      (PP (IN:[508..510] of)
        (NP (NN:[511..516] JM216) (NN:[517..528] monotherapy))))
    (VP (VBP:[529..533] have)
      (ADVP-TMP (RB:[534..541] already))
      (VP (VBN:[542..546] been)
        (VP (VBN:[547..555] reported)
          (NP-1 (-NONE-:[555..555] *)))))
    (.:[555..556] .)))

;sentence 6 Span:558..647
;However, no information on the potential drug interactions caused by JM216 is
; available.
;[599..603]:substance:"drug"
;[627..632]:substance:"JM216"
(SENT
  (S
    (ADVP (RB:[558..565] However))
    (,:[565..566] ,)
    (NP-SBJ
      (NP (DT:[567..569] no) (NN:[570..581] information))
      (PP (IN:[582..584] on)
        (NP
          (NP (DT:[585..588] the) (JJ:[589..598] potential) (NN:[599..603] drug)
              (NNS:[604..616] interactions))
          (VP (VBN:[617..623] caused)
            (NP (-NONE-:[623..623] *))
            (PP (IN:[624..626] by)
              (NP-LGS (NN:[627..632] JM216)))))))
    (VP (VBZ:[633..635] is)
      (ADJP-PRD (JJ:[637..646] available)))
    (.:[646..647] .)))

;sentence 7 Span:648..838
;In this study, the capacity of JM216 to inhibit cytochrome P450 (CYP)  in
;human liver microsomes was investigated by measuring the inhibition potential
; (IC50 and Ki) on prototype reactions.
;[679..684]:substance:"JM216"
;[696..711]:cyp450:"cytochrome P450"
;[713..716]:cyp450:"CYP"
;[802..806]:quantitative-name:"IC50"
;[811..813]:quantitative-name:"Ki"
(SENT
  (S
    (PP-LOC (IN:[648..650] In)
      (NP (DT:[651..655] this) (NN:[656..661] study)))
    (,:[661..662] ,)
    (NP-SBJ-1
      (NP (DT:[663..666] the) (NN:[667..675] capacity)
        (S-3 (-NONE-:[675..675] *ICH*)))
      (PP (IN:[676..678] of)
        (NP (NN:[679..684] JM216)))
      (S-3
        (NP-SBJ (-NONE-:[684..684] *))
        (VP (TO:[685..687] to)
          (VP (VB:[688..695] inhibit)
            (NP
              (NP (NN:[696..706] cytochrome) (NN:[707..711] P450))
              (NP (-LRB-:[712..713] -LRB-) (NN:[713..716] CYP)
                  (-RRB-:[716..717] -RRB-)))
            (PP-LOC (IN:[719..721] in)
              (NP (JJ:[722..727] human) (NN:[728..733] liver)
                  (NNS:[734..744] microsomes)))))))
    (VP (VBD:[745..748] was)
      (VP (VBN:[749..761] investigated)
        (NP-1 (-NONE-:[761..761] *))
        (PP-MNR (IN:[762..764] by)
          (S-NOM
            (NP-SBJ (-NONE-:[764..764] *))
            (VP (VBG:[765..774] measuring)
              (NP
                (NP (DT:[775..778] the) (NN:[779..789] inhibition)
                    (NN:[790..799] potential))
                (NP (-LRB-:[801..802] -LRB-) (NN:[802..806] IC50)
                    (CC:[807..810] and) (NN:[811..813] Ki)
                    (-RRB-:[813..814] -RRB-)))
              (PP (IN:[815..817] on)
                (NP (NN:[818..827] prototype) (NNS:[828..837] reactions))))))))
    (.:[837..838] .)))

;sentence 8 Span:839..1036
;Specific substrates of CYP included  testosterone (catalysed by CYP3A4),
;paclitaxel (CYP2C8), 7-ethoxyresorufin  (CYP1A1, CYP1A2), coumarin (CYP2A6),
;aniline (CYP2E1) and (+/-)-bufuralol  (CYP2D6).
;[848..858]:substance:"substrates"
;[862..865]:cyp450:"CYP"
;[876..888]:substance:"testosterone"
;[903..909]:cyp450:"CYP3A4"
;[912..922]:substance:"paclitaxel"
;[924..930]:cyp450:"CYP2C8"
;[933..950]:substance:"7-ethoxyresorufin"
;[953..959]:cyp450:"CYP1A1"
;[961..967]:cyp450:"CYP1A2"
;[970..978]:substance:"coumarin"
;[980..986]:cyp450:"CYP2A6"
;[989..996]:substance:"aniline"
;[998..1004]:cyp450:"CYP2E1"
;[1010..1025]:substance:"(+/-)-bufuralol"
;[1028..1034]:cyp450:"CYP2D6"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[839..847] Specific) (NNS:[848..858] substrates))
      (PP (IN:[859..861] of)
        (NP (NN:[862..865] CYP))))
    (VP (VBD:[866..874] included)
      (NP
        (NP (NN:[876..888] testosterone)
          (PRN (-LRB-:[889..890] -LRB-)
            (VP (VBN:[890..899] catalysed)
              (NP (-NONE-:[899..899] *))
              (PP (IN:[900..902] by)
                (NP-LGS (NN:[903..909] CYP3A4))))
            (-RRB-:[909..910] -RRB-)))
        (,:[910..911] ,)
        (NP (NN:[912..922] paclitaxel)
          (PRN (-LRB-:[923..924] -LRB-)
            (NP (NN:[924..930] CYP2C8))
            (-RRB-:[930..931] -RRB-)))
        (,:[931..932] ,)
        (NP (NN:[933..950] 7-ethoxyresorufin)
          (PRN (-LRB-:[952..953] -LRB-)
            (NP (NN:[953..959] CYP1A1) (,:[959..960] ,) (NN:[961..967] CYP1A2))
            (-RRB-:[967..968] -RRB-)))
        (,:[968..969] ,)
        (NP (NN:[970..978] coumarin)
          (PRN (-LRB-:[979..980] -LRB-)
            (NP (NN:[980..986] CYP2A6))
            (-RRB-:[986..987] -RRB-)))
        (,:[987..988] ,)
        (NP (NN:[989..996] aniline)
          (PRN (-LRB-:[997..998] -LRB-)
            (NP (NN:[998..1004] CYP2E1))
            (-RRB-:[1004..1005] -RRB-)))
        (CC:[1006..1009] and)
        (NP (NN:[1010..1025] -LRB-+/--RRB--bufuralol)
          (PRN (-LRB-:[1027..1028] -LRB-)
            (NP (NN:[1028..1034] CYP2D6))
            (-RRB-:[1034..1035] -RRB-)))))
    (.:[1035..1036] .)))

;sentence 9 Span:1037..1094
;JM216 inhibited the catalytic activities of CYP isozymes.
;[1037..1042]:substance:"JM216"
;[1081..1093]:cyp450:"CYP isozymes"
(SENT
  (S
    (NP-SBJ (NN:[1037..1042] JM216))
    (VP (VBD:[1043..1052] inhibited)
      (NP
        (NP (DT:[1053..1056] the) (JJ:[1057..1066] catalytic)
            (NNS:[1067..1077] activities))
        (PP (IN:[1078..1080] of)
          (NP (NN:[1081..1084] CYP) (NNS:[1085..1093] isozymes)))))
    (.:[1093..1094] .)))

;sentence 10 Span:1095..1215
;The IC50  values were between 0.3 microM and 10 microM, indicating strong and
;non-specific  inhibitory effects of JM216.
;[1099..1103]:quantitative-name:"IC50"
;[1125..1128]:quantitative-value:"0.3"
;[1129..1135]:quantitative-units:"microM"
;[1140..1142]:quantitative-value:"10"
;[1143..1149]:quantitative-units:"microM"
;[1209..1214]:substance:"JM216"
(SENT
  (S
    (NP-SBJ (DT:[1095..1098] The) (NN:[1099..1103] IC50)
            (NNS:[1105..1111] values))
    (VP (VBD:[1112..1116] were)
      (PP-PRD (IN:[1117..1124] between)
        (NP
          (NP (CD:[1125..1128] 0.3) (NN:[1129..1135] microM))
          (CC:[1136..1139] and)
          (NP (CD:[1140..1142] 10) (NN:[1143..1149] microM))))
      (,:[1149..1150] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1150..1150] *))
        (VP (VBG:[1151..1161] indicating)
          (NP
            (NP
              (ADJP
                (ADJP (JJ:[1162..1168] strong))
                (CC:[1169..1172] and)
                (ADJP (AFX:[1173..1176] non) (HYPH:[1176..1177] -)
                      (JJ:[1177..1185] specific)))
              (JJ:[1187..1197] inhibitory) (NNS:[1198..1205] effects))
            (PP (IN:[1206..1208] of)
              (NP (NN:[1209..1214] JM216)))))))
    (.:[1214..1215] .)))

;sentence 11 Span:1216..1380
;The inhibition occurred in a non-competitive  manner, and the Ki value was
;1.0 and 0.9 microM for metabolite formation of  testosterone and paclitaxel
;respectively.
;[1278..1280]:quantitative-name:"Ki"
;[1291..1294]:quantitative-value:"1.0"
;[1299..1302]:quantitative-value:"0.9"
;[1303..1309]:quantitative-units:"microM"
;[1314..1324]:substance:"metabolite"
;[1339..1351]:substance:"testosterone"
;[1356..1366]:substance:"paclitaxel"
(SENT
  (S
    (S
      (NP-SBJ (DT:[1216..1219] The) (NN:[1220..1230] inhibition))
      (VP (VBD:[1231..1239] occurred)
        (PP-MNR (IN:[1240..1242] in)
          (NP (DT:[1243..1244] a)
            (ADJP (AFX:[1245..1248] non) (HYPH:[1248..1249] -)
                  (JJ:[1249..1260] competitive))
            (NN:[1262..1268] manner)))))
    (,:[1268..1269] ,) (CC:[1270..1273] and)
    (S
      (NP-SBJ (DT:[1274..1277] the) (NN:[1278..1280] Ki) (NN:[1281..1286] value))
      (VP (VBD:[1287..1290] was)
        (NP-PRD
          (NP (CD:[1291..1294] 1.0)
            (NML-1 (-NONE-:[1294..1294] *P*)))
          (CC:[1295..1298] and)
          (NP (CD:[1299..1302] 0.9)
            (NML-1 (NN:[1303..1309] microM))))
        (PP (IN:[1310..1313] for)
          (NP
            (NP (NN:[1314..1324] metabolite) (NN:[1325..1334] formation))
            (PP (IN:[1335..1337] of)
              (NP (NN:[1339..1351] testosterone) (CC:[1352..1355] and)
                  (NN:[1356..1366] paclitaxel)))))
        (ADVP (RB:[1367..1379] respectively))))
    (.:[1379..1380] .)))

;sentence 12 Span:1381..1523
;Therefore, some in vivo studies should  be conducted to determine whether or
;not there is a correlation between in vivo  and in vitro results.
(SENT
  (S
    (ADVP (RB:[1381..1390] Therefore))
    (,:[1390..1391] ,)
    (NP-SBJ-2 (DT:[1392..1396] some)
      (ADJP (FW:[1397..1399] in) (FW:[1400..1404] vivo))
      (NNS:[1405..1412] studies))
    (VP (MD:[1413..1419] should)
      (VP (VB:[1421..1423] be)
        (VP (VBN:[1424..1433] conducted)
          (NP-2 (-NONE-:[1433..1433] *))
          (S-PRP
            (NP-SBJ (-NONE-:[1433..1433] *))
            (VP (TO:[1434..1436] to)
              (VP (VB:[1437..1446] determine)
                (SBAR (IN:[1447..1454] whether) (CC:[1455..1457] or)
                      (RB:[1458..1461] not)
                  (S
                    (NP-SBJ (EX:[1462..1467] there))
                    (PP (VBZ:[1468..1470] is)
                      (NP-PRD
                        (NP (DT:[1471..1472] a) (NN:[1473..1484] correlation))
                        (PP (IN:[1485..1492] between)
                          (NP
                            (NP
                              (ADJP (FW:[1493..1495] in) (FW:[1496..1500] vivo))
                              (NML-1 (-NONE-:[1500..1500] *P*)))
                            (CC:[1502..1505] and)
                            (NP
                              (ADJP (FW:[1506..1508] in) (FW:[1509..1514] vitro))
                              (NML-1 (NNS:[1515..1522] results)))))))))))))))
    (.:[1522..1523] .)))

;section 13 Span:1527..1571
;PMID: 9820175 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1527..1531] PMID) (::[1531..1532] :) (CD:[1533..1540] 9820175)
        (NN:[1541..1542] -LSB-) (NNP:[1542..1548] PubMed) (::[1549..1550] -)
        (NN:[1551..1558] indexed) (IN:[1559..1562] for)
        (NNP:[1563..1571] MEDLINE-RSB-)))
